Empagliflozin suppresses inflammation and protects against acute septic renal injury

ConclusionOverall, the findings of this study suggest that empagliflozin could be repurposed to reduce morbidity and mortality in patients with acute septic renal injury.Trial registrationNot applicable.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research